Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial

Yuankai Shi; Kaijian Lei; Yuming Jia; Bingqiang Ni; Zhiyong He; Minghong Bi; Xicheng Wang; Jianhua Shi; Ming Zhou; Qian Sun; Guolei Wang; Dongji Chen; Yongqian Shu; Lianke Liu; Zhongliang Guo; Yong Liu; Junquan Yang; Ke Wang; Ke Xiao; Lin Wu; Tienan Yi; Debin Sun; Mafei Kang; Tianjiang Ma; Yimin Mao; Jinsheng Shi; Tiegang Tang; Yan Wang; Puyuan Xing; Dongqing Lv; Wangjun Liao; Zhiguo Luo; Bin Wang; Xiaohong Wu; Xiaoli Zhu; Shuhua Han; Qisen Guo; Rongyu Liu; Zhiwei Lu; Jianyong Zhang; Jian Fang; Changlu Hu; Yinghua Ji; Guolong Liu; Hong Lu; Dedong Wu; Junhong Zhang; Shuyang Zhu; Zheng Liu; Wensheng Qiu; Feng Ye; Yan Yu; Yanqiu Zhao; Qinhong Zheng; Jun Chen; Zhanyu Pan; Yiping Zhang; Wenjuan Lian; Bo Jiang; Bo Qiu; Guojun Zhang; Hua Zhang; Yanju Chen; Yuan Chen; Hongbing Duan; Manxiang Li; Shengming Liu; Lijun Ma; Hongming Pan; Xia Yuan; Xueli Yuan; Yulong Zheng; Emei Gao; Li Zhao; Shumin Wang; Can Wu

doi:10.1002/cac2.12179

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial

Yuankai Shi
, Kaijian Lei
, Yuming Jia
, Bingqiang Ni
, Zhiyong He
, Minghong Bi
, Xicheng Wang
, Jianhua Shi
, Ming Zhou
, Qian Sun
, Guolei Wang
, Dongji Chen
, Yongqian Shu
, Lianke Liu
, Zhongliang Guo
, Yong Liu
, Junquan Yang
, Ke Wang
, Ke Xiao
, Lin Wu

Tienan Yi, Debin Sun, Mafei Kang, Tianjiang Ma, Yimin Mao, Jinsheng Shi, Tiegang Tang, Yan Wang, Puyuan Xing, Dongqing Lv, Wangjun Liao, Zhiguo Luo, Bin Wang, Xiaohong Wu, Xiaoli Zhu, Shuhua Han, Qisen Guo, Rongyu Liu, Zhiwei Lu, Jianyong Zhang, Jian Fang, Changlu Hu, Yinghua Ji, Guolong Liu, Hong Lu, Dedong Wu, Junhong Zhang, Shuyang Zhu, Zheng Liu, Wensheng Qiu, Feng Ye, Yan Yu, Yanqiu Zhao, Qinhong Zheng, Jun Chen, Zhanyu Pan, Yiping Zhang, Wenjuan Lian, Bo Jiang, Bo Qiu, Guojun Zhang, Hua Zhang, Yanju Chen, Yuan Chen, Hongbing Duan, Manxiang Li, Shengming Liu, Lijun Ma, Hongming Pan, Xia Yuan, Xueli Yuan, Yulong Zheng, Emei Gao, Li Zhao, Shumin Wang, Can Wu

Chinese Academy of Medical Sciences
The Second People's Hospital of Yibin
Luzhou People’s Hospital
Fujian Provincial Cancer Hospital
Bengbu Medical College
Guangdong Pharmaceutical University
Linyi Cancer Hospital
Guangzhou Medical College
Henan Chest Hospital
Wuwei Cancer Hospital of Gansu Province
The First Affiliated Hospital with Nanjing Medical University
Shanghai East Hospital of Tongji University
Xuzhou Central Hospital
Tangshan People's Hospital
Sichuan University
The Second Affiliated Hospital of Shantou University Medical College
Central South University
Xiangyang Central Hospital
Lishui Central Hospital
Guilin Medical College
Luohe Central Hospital
Henan University of Science and Technology
Cangzhou People's Hospital
Xiangtan Central Hospital
Taizhou Hospital
Nanfang Hospital
Taihe Hospital of Shiyan City
Huzhou Central Hospital
the Fourth People's Hospital of Wuxi City
Zhongda Hospital Southeast University
Shandong Cancer Hospital
Anhui Medical University
Wannan Medical College
Zunyi Medical University
Peking University
Anhui Cancer Hospital
Xinxiang Medical College
Guangzhou First People's Hospital
Henan University
Henan Provincial People's Hospital
Zhongnan Hospital of Wuhan University
Xuzhou Medical University
Handan Central Hospital
Qingdao University
The First Affiliated Hospital of Xiamen University
Harbin Medical University
Henan Cancer Hospital
Quzhou People's Hospital
Tianjin Medical University
Zhejiang Cancer Hospital
Xi'an Chest Hospital
Yunnan Cancer Hospital
Zhuzhou Central Hospital
First Affiliated Hospital of Zhengzhou University
Xinjiang Medical University
People's Hospital of Hainan Province
Huazhong University of Science and Technology
Zhongshan Hospital Affiliated to Xiamen University
The First Affiliated Hospital of Xi’an Jiaotong University
The First Affiliated Hospital of Jinan University
Shanghai Jiao Tong University
Zhejiang University
HuiZhou Municipal Central Hospital
Huai'an Second People's Hospital
Clinical Research Center of Luye Pharma Group Ltd

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Background: Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Methods: Stage IIIB-IV NSCLC patients with evaluable lesions, good physical status, and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin (combined treatment) for 4-6 cycles, followed by maintenance monotherapy with LY01008 until disease progression, intolerable toxicity, or death. The primary endpoint was objective response rate (ORR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by independent radiological review committees (IRRC). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. This study was registered in ClinicalTrials.gov (NCT03533127). Results: Between December 15^th, 2017, and May 15^th, 2019, a total of 649 patients were randomized to the LY01008 (n = 324) or Avastin (n = 325) group. As of September 25^th, 2019 for primary endpoint analysis, 589 patients received ORR evaluation, with a median number of combined treatment cycles of 5 (range 1-6) and median duration of treatment of 3.0 (range 0.0-5.1) months. ORR of response-evaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%, respectively. The stratified ORR ratio was 0.91 (90% CI 0.80-1.04, within the prespecified equivalence margin of 0.75-1.33). Up to May 15^th, 2020, with a median follow-up of 13.6 (range 0.8-28.4) months, no notable differences in DCR, median DoR, median PFS, median OS, and 1-year OS rate were observed between the LY01008 and Avastin groups. There were no clinically meaningful differences in safety and immunogenicity across treatment groups. Conclusions: LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC. LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable, metastatic, or recurrent non-squamous NSCLC patients in the first-line setting.

Original language	English
Pages (from-to)	889-903
Number of pages	15
Journal	Cancer Communications
Volume	41
Issue number	9
DOIs	https://doi.org/10.1002/cac2.12179
State	Published - Sep 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

LY01008
anti-VEGF monoclonal antibody
anti-angiogenesis
avastin
bevacizumab
biosimilar
non-small cell lung cancer
vascular endothelial growth factor

Access to Document

10.1002/cac2.12179

Fingerprint

Dive into the research topics of 'Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial'. Together they form a unique fingerprint.

Cite this

Shi, Y., Lei, K., Jia, Y., Ni, B., He, Z., Bi, M., Wang, X., Shi, J., Zhou, M., Sun, Q., Wang, G., Chen, D., Shu, Y., Liu, L., Guo, Z., Liu, Y., Yang, J., Wang, K., Xiao, K., ... Wu, C. (2021). Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial. Cancer Communications, 41(9), 889-903. https://doi.org/10.1002/cac2.12179

Shi, Yuankai ; Lei, Kaijian ; Jia, Yuming et al. / Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer : A multicenter, randomized, double-blinded, phase III trial. In: Cancer Communications. 2021 ; Vol. 41, No. 9. pp. 889-903.

@article{2a2efb2addf3471c9c0b46eb6ef5050b,

title = "Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial",

abstract = "Background: Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Methods: Stage IIIB-IV NSCLC patients with evaluable lesions, good physical status, and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin (combined treatment) for 4-6 cycles, followed by maintenance monotherapy with LY01008 until disease progression, intolerable toxicity, or death. The primary endpoint was objective response rate (ORR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by independent radiological review committees (IRRC). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. This study was registered in ClinicalTrials.gov (NCT03533127). Results: Between December 15th, 2017, and May 15th, 2019, a total of 649 patients were randomized to the LY01008 (n = 324) or Avastin (n = 325) group. As of September 25th, 2019 for primary endpoint analysis, 589 patients received ORR evaluation, with a median number of combined treatment cycles of 5 (range 1-6) and median duration of treatment of 3.0 (range 0.0-5.1) months. ORR of response-evaluable patients in the LY01008 and Avastin groups were 48.5\% and 53.0\%, respectively. The stratified ORR ratio was 0.91 (90\% CI 0.80-1.04, within the prespecified equivalence margin of 0.75-1.33). Up to May 15th, 2020, with a median follow-up of 13.6 (range 0.8-28.4) months, no notable differences in DCR, median DoR, median PFS, median OS, and 1-year OS rate were observed between the LY01008 and Avastin groups. There were no clinically meaningful differences in safety and immunogenicity across treatment groups. Conclusions: LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC. LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable, metastatic, or recurrent non-squamous NSCLC patients in the first-line setting.",

keywords = "LY01008, anti-VEGF monoclonal antibody, anti-angiogenesis, avastin, bevacizumab, biosimilar, non-small cell lung cancer, vascular endothelial growth factor",

author = "Yuankai Shi and Kaijian Lei and Yuming Jia and Bingqiang Ni and Zhiyong He and Minghong Bi and Xicheng Wang and Jianhua Shi and Ming Zhou and Qian Sun and Guolei Wang and Dongji Chen and Yongqian Shu and Lianke Liu and Zhongliang Guo and Yong Liu and Junquan Yang and Ke Wang and Ke Xiao and Lin Wu and Tienan Yi and Debin Sun and Mafei Kang and Tianjiang Ma and Yimin Mao and Jinsheng Shi and Tiegang Tang and Yan Wang and Puyuan Xing and Dongqing Lv and Wangjun Liao and Zhiguo Luo and Bin Wang and Xiaohong Wu and Xiaoli Zhu and Shuhua Han and Qisen Guo and Rongyu Liu and Zhiwei Lu and Jianyong Zhang and Jian Fang and Changlu Hu and Yinghua Ji and Guolong Liu and Hong Lu and Dedong Wu and Junhong Zhang and Shuyang Zhu and Zheng Liu and Wensheng Qiu and Feng Ye and Yan Yu and Yanqiu Zhao and Qinhong Zheng and Jun Chen and Zhanyu Pan and Yiping Zhang and Wenjuan Lian and Bo Jiang and Bo Qiu and Guojun Zhang and Hua Zhang and Yanju Chen and Yuan Chen and Hongbing Duan and Manxiang Li and Shengming Liu and Lijun Ma and Hongming Pan and Xia Yuan and Xueli Yuan and Yulong Zheng and Emei Gao and Li Zhao and Shumin Wang and Can Wu",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Cancer Communications published by John Wiley \& Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center",

year = "2021",

month = sep,

doi = "10.1002/cac2.12179",

language = "英语",

volume = "41",

pages = "889--903",

journal = "Cancer Communications",

issn = "2523-3548",

publisher = "American Association for the Advancement of Science",

number = "9",

}

Shi, Y, Lei, K, Jia, Y, Ni, B, He, Z, Bi, M, Wang, X, Shi, J, Zhou, M, Sun, Q, Wang, G, Chen, D, Shu, Y, Liu, L, Guo, Z, Liu, Y, Yang, J, Wang, K, Xiao, K, Wu, L, Yi, T, Sun, D, Kang, M, Ma, T, Mao, Y, Shi, J, Tang, T, Wang, Y, Xing, P, Lv, D, Liao, W, Luo, Z, Wang, B, Wu, X, Zhu, X, Han, S, Guo, Q, Liu, R, Lu, Z, Zhang, J, Fang, J, Hu, C, Ji, Y, Liu, G, Lu, H, Wu, D, Zhang, J, Zhu, S, Liu, Z, Qiu, W, Ye, F, Yu, Y, Zhao, Y, Zheng, Q, Chen, J, Pan, Z, Zhang, Y, Lian, W, Jiang, B, Qiu, B, Zhang, G, Zhang, H, Chen, Y, Chen, Y, Duan, H, Li, M, Liu, S, Ma, L, Pan, H, Yuan, X, Yuan, X, Zheng, Y, Gao, E, Zhao, L, Wang, S & Wu, C 2021, 'Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial', Cancer Communications, vol. 41, no. 9, pp. 889-903. https://doi.org/10.1002/cac2.12179

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial. / Shi, Yuankai; Lei, Kaijian; Jia, Yuming et al.
In: Cancer Communications, Vol. 41, No. 9, 09.2021, p. 889-903.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer

T2 - A multicenter, randomized, double-blinded, phase III trial

AU - Shi, Yuankai

AU - Lei, Kaijian

AU - Jia, Yuming

AU - Ni, Bingqiang

AU - He, Zhiyong

AU - Bi, Minghong

AU - Wang, Xicheng

AU - Shi, Jianhua

AU - Zhou, Ming

AU - Sun, Qian

AU - Wang, Guolei

AU - Chen, Dongji

AU - Shu, Yongqian

AU - Liu, Lianke

AU - Guo, Zhongliang

AU - Liu, Yong

AU - Yang, Junquan

AU - Wang, Ke

AU - Xiao, Ke

AU - Wu, Lin

AU - Yi, Tienan

AU - Sun, Debin

AU - Kang, Mafei

AU - Ma, Tianjiang

AU - Mao, Yimin

AU - Shi, Jinsheng

AU - Tang, Tiegang

AU - Wang, Yan

AU - Xing, Puyuan

AU - Lv, Dongqing

AU - Liao, Wangjun

AU - Luo, Zhiguo

AU - Wang, Bin

AU - Wu, Xiaohong

AU - Zhu, Xiaoli

AU - Han, Shuhua

AU - Guo, Qisen

AU - Liu, Rongyu

AU - Lu, Zhiwei

AU - Zhang, Jianyong

AU - Fang, Jian

AU - Hu, Changlu

AU - Ji, Yinghua

AU - Liu, Guolong

AU - Lu, Hong

AU - Wu, Dedong

AU - Zhang, Junhong

AU - Zhu, Shuyang

AU - Liu, Zheng

AU - Qiu, Wensheng

AU - Ye, Feng

AU - Yu, Yan

AU - Zhao, Yanqiu

AU - Zheng, Qinhong

AU - Chen, Jun

AU - Pan, Zhanyu

AU - Zhang, Yiping

AU - Lian, Wenjuan

AU - Jiang, Bo

AU - Qiu, Bo

AU - Zhang, Guojun

AU - Zhang, Hua

AU - Chen, Yanju

AU - Chen, Yuan

AU - Duan, Hongbing

AU - Li, Manxiang

AU - Liu, Shengming

AU - Ma, Lijun

AU - Pan, Hongming

AU - Yuan, Xia

AU - Yuan, Xueli

AU - Zheng, Yulong

AU - Gao, Emei

AU - Zhao, Li

AU - Wang, Shumin

AU - Wu, Can

PY - 2021/9

Y1 - 2021/9

N2 - Background: Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Methods: Stage IIIB-IV NSCLC patients with evaluable lesions, good physical status, and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin (combined treatment) for 4-6 cycles, followed by maintenance monotherapy with LY01008 until disease progression, intolerable toxicity, or death. The primary endpoint was objective response rate (ORR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by independent radiological review committees (IRRC). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. This study was registered in ClinicalTrials.gov (NCT03533127). Results: Between December 15th, 2017, and May 15th, 2019, a total of 649 patients were randomized to the LY01008 (n = 324) or Avastin (n = 325) group. As of September 25th, 2019 for primary endpoint analysis, 589 patients received ORR evaluation, with a median number of combined treatment cycles of 5 (range 1-6) and median duration of treatment of 3.0 (range 0.0-5.1) months. ORR of response-evaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%, respectively. The stratified ORR ratio was 0.91 (90% CI 0.80-1.04, within the prespecified equivalence margin of 0.75-1.33). Up to May 15th, 2020, with a median follow-up of 13.6 (range 0.8-28.4) months, no notable differences in DCR, median DoR, median PFS, median OS, and 1-year OS rate were observed between the LY01008 and Avastin groups. There were no clinically meaningful differences in safety and immunogenicity across treatment groups. Conclusions: LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC. LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable, metastatic, or recurrent non-squamous NSCLC patients in the first-line setting.

AB - Background: Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Methods: Stage IIIB-IV NSCLC patients with evaluable lesions, good physical status, and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin (combined treatment) for 4-6 cycles, followed by maintenance monotherapy with LY01008 until disease progression, intolerable toxicity, or death. The primary endpoint was objective response rate (ORR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by independent radiological review committees (IRRC). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. This study was registered in ClinicalTrials.gov (NCT03533127). Results: Between December 15th, 2017, and May 15th, 2019, a total of 649 patients were randomized to the LY01008 (n = 324) or Avastin (n = 325) group. As of September 25th, 2019 for primary endpoint analysis, 589 patients received ORR evaluation, with a median number of combined treatment cycles of 5 (range 1-6) and median duration of treatment of 3.0 (range 0.0-5.1) months. ORR of response-evaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%, respectively. The stratified ORR ratio was 0.91 (90% CI 0.80-1.04, within the prespecified equivalence margin of 0.75-1.33). Up to May 15th, 2020, with a median follow-up of 13.6 (range 0.8-28.4) months, no notable differences in DCR, median DoR, median PFS, median OS, and 1-year OS rate were observed between the LY01008 and Avastin groups. There were no clinically meaningful differences in safety and immunogenicity across treatment groups. Conclusions: LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC. LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable, metastatic, or recurrent non-squamous NSCLC patients in the first-line setting.

KW - LY01008

KW - anti-VEGF monoclonal antibody

KW - anti-angiogenesis

KW - avastin

KW - bevacizumab

KW - biosimilar

KW - non-small cell lung cancer

KW - vascular endothelial growth factor

UR - https://www.scopus.com/pages/publications/85108830092

U2 - 10.1002/cac2.12179

DO - 10.1002/cac2.12179

M3 - 文章

C2 - 34184418

AN - SCOPUS:85108830092

SN - 2523-3548

VL - 41

SP - 889

EP - 903

JO - Cancer Communications

JF - Cancer Communications

IS - 9

ER -

Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M et al. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial. Cancer Communications. 2021 Sep;41(9):889-903. doi: 10.1002/cac2.12179

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non–small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this